Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Viking Therapeutics, Inc. (VKTX)
Last viking therapeutics, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vikingtherapeutics.com
Company Research
Source: Yahoo! Finance
to 13.1% Placebo-Adjusted Weight Loss (14.7% From Baseline) at 13 Weeks; Shown to be Safe and Well-Tolerated Results From Phase 1 Trial of Oral VK2735 Demonstrated Promising Safety and Tolerability With Up to 3.3% Placebo-Adjusted Weight Loss (5.3% From Baseline) at 28 Days 52-Week Histology Results From Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis Expected in 2Q24 Completed Public Offering of Common Stock Raising Gross Proceeds of Approximately $630 Million Quarter-End Cash Position of $963 Million SAN DIEGO April 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2024 , and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter Ended March 31, 2024 , and Other Re
Show less
Read more
Impact Snapshot
Event Time:
VKTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VKTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VKTX alerts
High impacting Viking Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VKTX
News
- Can This High-Flying Stock 10x in 10 Years? [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- 11 Oversold MidCap Stocks To Buy Now [Yahoo! Finance]Yahoo! Finance
- Viking Therapeutics, Inc. (NASDAQ: VKTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.MarketBeat
- Viking Therapeutics, Inc. (NASDAQ: VKTX) was upgraded by analysts at StockNews.com to a "sell" rating.MarketBeat
VKTX
Earnings
- 4/24/24 - Beat
VKTX
Sec Filings
- 5/3/24 - Form 4
- 5/3/24 - Form 144
- 5/2/24 - Form 4
- VKTX's page on the SEC website